Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | DRD3 | P35462 | 9/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 6/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547385 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL29429678 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL43366 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL895742 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL6824058 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL31672141 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL6824054 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL3468007 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL9315535 | 0.90 | DRD2 (0.82) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL4210081 | 0.88 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113234057-B | Preparation method of rotigotine | 成都工业学院 | 2022-12-02 | — | — | CN | claimed |
| CN-113234057-A | Preparation method of rotigotine | 成都工业学院 | 2021-08-10 | — | — | CN | claimed |
| US-20110313176-A1 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | claimed |
| WO-2010073124-A2 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-07-01 | — | — | WO | claimed |
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| CN-116621775-A | 2-amino-5-hydroxytetrahydronaphthalene derivative containing hydroxypyridone side chain, preparation and application thereof | 浙江大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116438169-A | Serotonin receptor modulators | 东北大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-113234057-B | Preparation method of rotigotine | 成都工业学院 | 2022-12-02 | — | — | CN | disclosed |
| CN-114249663-A | Method for preparing (S) -2-amino-5-methoxy naphthalene mandelate by continuous flow reactor | 安徽皓元药业有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-113234057-A | Preparation method of rotigotine | 成都工业学院 | 2021-08-10 | — | — | CN | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
| JP-2002187875-A | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-AMINO-5- METHOXYTETRALIN | NAGASE & CO LTD | 2002-07-05 | — | — | JP | disclosed |
| EP-0717620-B1 | SUBSTITUTED 2-AMINOTETRALINS | DISCOVERY THERAPEUTICS INC (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0717620-A4 | SUBSTITUTED 2-AMINOTETRALINS | DISCOVERY THERAPEUTICS INC (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0717620-A1 | SUBSTITUTED 2-AMINOTETRALINS | Discovery Therapeutics, Inc. (US) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995004532-A1 | SUBSTITUTED 2-AMINOTETRALINS | DISCOVERY THERAPEUTICS INC. (US) | 1995-02-16 | — | — | WO | disclosed |
| US-5382596-A | Useful for alleviating Parkinsonism, glaucoma, hyperprolactinemia and for inducing weight loss in mammals | WHITBY RESEARCH, INC. (US) | 1995-01-17 | — | — | US | disclosed |
| US-5300437-A | Using omega-amino acid transaminase | CELGENE CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | HTR7, HTR2C, HTR6 | DRD2 264/4885DRD3 370/4885ADRA1A 133/4885 |
| US-20230348358-A1 | Serotonin Receptor Modulators | HTR7, HTR1A, HTR5A | DRD2 298/4885DRD3 834/4885ADRA1A 351/4885 |
| US-20110313176-A1 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC4R, AVPR2, MC5R | DRD2 100/4885DRD3 216/4885ADRA1A 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.